The STRIDE Study: Concurrent vs Sequential Enzalutamide With Sipuleucel-T for mCRPC
Daniel P. Petrylak, MD, discusses the results of the phase II STRIDE study in metastatic castration-resistant prostate cancer (mCRPC).
Clinical Pearls
Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses the results of thephase II STRIDE studyin metastatic castration-resistant prostate cancer (mCRPC).
- The STRIDE study evaluated concurrent versus sequential enzalutamide in combination with sipuleucel-T for mCRPC.
- There was no difference seen in immune parameters when comparing early and delayed enzalutamide. The prime-boost effect was similar in the two arms.
- Anecdotally, no additive or synergistic toxicities were observed. Full toxicity data will be reported later.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More
